Molecure S.A. (1B1.F)

3.2300 -0.0450 (-1.37%) As of 08:24AM CEST. Market open.

Molecure S.A.

Zwirki i Wigury 101
Warsaw 02-089
Poland
48 225 52 67 24
https://molecure.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 109

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Marcin Jan Szumowski Ph.D.	Co-Founder, CEO & President of Management Board	N/A	N/A	N/A
Mr. Adam Golebiowski Ph.D.	Co-Founder & VP of Research Chemistry	N/A	N/A	N/A
Mr. Slawomir Piotr Broniarek	CFO & Member of the Management Board	N/A	N/A	N/A
Mr. Zbigniew Zaslona	Chief Scientific Officer & Member of Management Board	N/A	N/A	N/A
Ms. Agnieszka Rajczuk-Szczepanska	Member of Management Board & HR Director	N/A	N/A	N/A
Mr. Jacek Olczak Ph.D.	Co-Founder & Head of Medicinal Chemistry	N/A	N/A	N/A
Dr. Samson Fung M.D.	Chief Medical Officer & Member of Management Board	N/A	N/A	N/A
Ms. Magdalena Tyszkiewicz	Head of CMC	N/A	N/A	N/A
Ms. Marta Borkowska	Director of the Management Board Office	N/A	N/A	N/A

Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.

Corporate Governance

Molecure S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.